Atypical haemolytic uraemic syndrome – Diagnostics – Overview of Information and Clinical Research

Diagnosing atypical hemolytic uremic syndrome requires careful evaluation and specialized testing, as this rare condition affects the blood vessels and kidneys in ways that can be difficult to distinguish from other diseases. Early and accurate diagnosis is essential for starting the right treatment and preventing serious complications.

Introduction: When to Seek Diagnostics

Atypical hemolytic uremic syndrome can affect people at any age, from newborns to older adults, though certain situations make diagnosis more urgent. Anyone experiencing unexplained symptoms like extreme tiredness, pale skin, decreased urination, or blood in the urine should seek medical attention promptly. These signs might seem vague at first, and many people feel as though they’ve been unwell for a while without understanding why.^[1]

People who have a family history of aHUS should be particularly vigilant. Because this condition often involves genetic mutations, biological relatives of someone diagnosed with aHUS may carry similar genetic changes. Even though having a mutation doesn’t automatically mean someone will develop the disease, it’s important for these individuals to be aware of potential symptoms. Pregnancy, infections, certain medications, or cancer can trigger the condition in people who carry these genetic changes.^[1]

Women who are pregnant or planning pregnancy should discuss their risk with healthcare providers, especially if aHUS runs in their family. Pregnancy is a known trigger for aHUS episodes, and being prepared with proper medical monitoring can make a significant difference. Similarly, anyone about to start medications that affect the immune system, blood clotting, or inflammation should inform their doctor about any family history of blood or kidney disorders.^[1]

⚠️ Important

Diagnosing atypical hemolytic uremic syndrome can be challenging because its symptoms often develop gradually or appear similar to other conditions. Some people experience only a few symptoms initially, or the signs come on so slowly that they seem like a persistent illness that won’t go away. Because early treatment is crucial for preventing permanent kidney damage, it’s important not to delay seeking medical evaluation when unusual symptoms appear, especially if you have a family history of kidney or blood disorders.

Classic Diagnostic Methods for Identifying aHUS

Healthcare providers typically diagnose atypical hemolytic uremic syndrome by looking for a specific pattern of three conditions occurring together. This combination includes microangiopathic hemolytic anemia (when red blood cells are destroyed faster than the body can replace them), thrombocytopenia (too few platelets in the blood), and acute kidney injury (a sudden decline in kidney function). When doctors see these three problems appearing simultaneously, they begin investigating whether aHUS might be the cause.^[1]

The diagnostic process usually begins with blood tests. A complete blood count reveals whether platelet levels are abnormally low and whether there’s evidence of anemia. Doctors look specifically for damaged red blood cells called schistocytes, which appear broken or fragmented under a microscope. These damaged cells are a hallmark sign that something is destroying blood cells as they travel through small blood vessels.^[7]

Additional blood tests measure the level of lactate dehydrogenase, or LDH, which is a chemical released when cells are damaged. High LDH levels suggest that cells are breaking down at an increased rate. Doctors also check haptoglobin, a protein that normally binds to hemoglobin released from damaged red blood cells. Low haptoglobin levels indicate that red blood cells are being destroyed, because the haptoglobin is being used up faster than the body can produce it.^[7]

Kidney function is assessed through blood tests that measure creatinine, a waste product that healthy kidneys normally filter out. When creatinine levels rise higher than normal, it signals that the kidneys aren’t working properly. This is especially concerning in aHUS, where blood clots in small kidney vessels can lead to kidney failure if not treated quickly.^[7]

Urine tests provide additional important information. Healthcare providers look for protein or blood in the urine, which shouldn’t normally be present. The appearance of these substances suggests that the kidneys’ filtering system has been damaged. This type of injury, called proteinuria when protein is found in urine, is common in people with aHUS.^[7]

One crucial test helps distinguish atypical HUS from a similar-looking condition called thrombotic thrombocytopenic purpura, or TTP. This test measures the activity of an enzyme called ADAMTS13. In TTP, this enzyme is severely deficient, but in aHUS, ADAMTS13 levels are usually normal or only slightly reduced. Running this test helps doctors choose the correct treatment path, because TTP and aHUS require different therapeutic approaches.^[8]

Stool samples may be examined to rule out typical hemolytic uremic syndrome, which is caused by certain strains of bacteria like E. coli O157:H7. These bacteria produce toxins called Shiga toxins that can trigger a form of HUS that typically follows severe diarrhea. If stool tests come back negative for these toxin-producing bacteria and the patient hasn’t had bloody diarrhea, doctors lean toward a diagnosis of atypical rather than typical HUS.^[12]

Physical examination findings also contribute to diagnosis. Doctors check blood pressure, as many people with aHUS develop hypertension, or high blood pressure. They look for swelling in the legs, feet, or other parts of the body, a condition called edema that occurs when kidneys can’t properly remove excess fluid. Some patients show signs of confusion or other neurological symptoms, though these are less common.^[1]

Genetic testing plays an important role in confirming the diagnosis and understanding the underlying cause. Mutations in genes that control complement proteins—parts of the immune system—are found in about half of all aHUS cases. The most commonly affected genes include CFH (complement factor H), CFI (complement factor I), C3 (complement component 3), and CFB (complement factor B). Identifying which gene is mutated can help predict how the disease might progress and guide treatment decisions.^[6]

In some cases, healthcare providers test for autoantibodies, which are proteins that mistakenly attack the body’s own complement factors. Some people with aHUS don’t have genetic mutations but instead have developed antibodies against complement factor H. These antibodies interfere with the normal regulation of the immune system, leading to the same type of blood vessel damage seen in genetically caused aHUS.^[3]

Blood pressure monitoring and assessment of other organs is important because aHUS can affect more than just the kidneys. While kidney problems are the most common, blood clots can form in small vessels throughout the body, potentially affecting the brain, heart, liver, lungs, and digestive system. Doctors may order additional tests if they suspect these organs are involved, though kidney and blood problems remain the primary focus of initial diagnosis.^[7]

Diagnostic Tests for Clinical Trial Qualification

When patients with atypical hemolytic uremic syndrome consider participating in clinical trials, they typically undergo a standardized set of diagnostic tests that help researchers determine eligibility and establish baseline measurements. These tests ensure that participants meet specific criteria and allow scientists to accurately measure how well experimental treatments work.

Estimated glomerular filtration rate, abbreviated as eGFR, is a key measurement used in clinical trials. This test calculates how well the kidneys are filtering waste from the blood based on creatinine levels, age, sex, and sometimes race. The eGFR provides a number that indicates the stage of kidney disease, which is crucial for determining whether someone’s kidney function is severe enough or too severe for certain trial protocols.^[8]

Complete blood counts are performed repeatedly in clinical trials to track changes in red blood cells, white blood cells, and platelets over time. Researchers need to document the baseline levels of these components before treatment begins, then monitor how they respond to experimental therapies. The presence of schistocytes, those fragmented red blood cells characteristic of aHUS, is carefully documented and tracked throughout the study period.^[8]

Lactate dehydrogenase levels are measured regularly in trials because they serve as a marker of how much cell destruction is occurring. As experimental treatments work to stop the disease process, LDH levels should decline. Researchers use these measurements to determine whether a new treatment is effectively reducing the breakdown of blood cells that characterizes aHUS.^[7]

Genetic testing is often required for enrollment in research studies. Trials may specifically recruit people with certain genetic mutations or exclude those with others, depending on what the study aims to investigate. Understanding each participant’s genetic background helps researchers analyze whether experimental treatments work better for some genetic variants than others. This information can eventually lead to more personalized treatment approaches.^[6]

Complement testing measures the activity levels of various complement system proteins. Since aHUS involves overactivation of the complement system, trials testing complement-blocking medications need detailed baseline measurements of complement activity. These tests show how active the immune system’s complement pathway is before treatment and help researchers determine the optimal dose of experimental medicines.^[3]

Kidney biopsy might be performed in some research settings, though it’s not always necessary for diagnosis or trial enrollment. This procedure involves taking a tiny sample of kidney tissue with a special needle. Examining the tissue under a microscope reveals the specific type and extent of damage to the kidney’s filtering structures and blood vessels. However, because kidney biopsies carry some risk, they’re typically reserved for cases where the diagnosis is unclear or when detailed tissue analysis is essential for the research question.^[3]

⚠️ Important

Clinical trials for atypical hemolytic uremic syndrome have strict inclusion and exclusion criteria to ensure participant safety and research validity. Some trials only accept people with specific genetic mutations, while others may exclude those with certain complications or those who have already received particular treatments. Understanding these requirements helps patients and their doctors determine which trials might be appropriate, though meeting eligibility criteria doesn’t guarantee that a treatment will be effective for any individual patient.

Blood pressure measurements are standardized in clinical trials, often requiring multiple readings at different times to establish an accurate baseline. Because many people with aHUS develop high blood pressure as a complication of kidney damage, monitoring blood pressure helps researchers understand whether experimental treatments protect the kidneys or have effects on blood pressure regulation. Some trials specifically track how often participants need blood pressure medications or whether doses can be reduced.^[1]

Urinalysis, the examination of urine, is performed regularly in clinical trials. Researchers measure protein levels in the urine to track kidney function and damage. They also look for blood cells or other abnormal substances that shouldn’t appear in healthy urine. Changes in these measurements over time help determine whether a treatment is protecting the kidneys or allowing further damage to occur.^[12]

Some trials require documentation of disease triggers or precipitating events that led to the current aHUS episode. Researchers collect detailed information about any infections, medications, pregnancies, or other factors that might have triggered the condition. This information helps scientists understand whether treatments work differently depending on what triggered the disease and whether preventing exposure to known triggers might reduce future episodes.^[1]

Quality of life assessments and symptom questionnaires are increasingly recognized as important outcome measures in clinical trials. Participants complete surveys about their energy levels, ability to perform daily activities, emotional wellbeing, and other factors that affect their lives. These subjective experiences matter as much as laboratory values when determining whether a treatment truly improves patients’ lives, not just their test results.^[17]

Prognosis and Survival Rate

Prognosis

The outlook for people with atypical hemolytic uremic syndrome has dramatically improved with modern treatments, though the disease remains serious and requires lifelong management. Before the availability of complement-blocking therapies, the prognosis was quite poor. Approximately 33 to 40 percent of patients developed end-stage renal disease or died during their first episode of aHUS, even with supportive care like plasma exchange. When considering both initial episodes and subsequent relapses, about two-thirds of patients required dialysis, experienced permanent kidney damage, or died within the first year after diagnosis.^[7]

The underlying genetic defect strongly influences prognosis. Mutations in different complement genes carry different risks for disease severity and recurrence. Some genetic variants are associated with more aggressive disease that responds less well to standard treatments, while others may cause milder forms of the condition. Understanding which gene is affected helps doctors predict how the disease might progress and make informed decisions about treatment intensity and duration.^[3]

The timing of diagnosis and treatment initiation significantly affects outcomes. When aHUS is recognized early and appropriate treatment begins quickly, patients have a much better chance of recovering kidney function and avoiding permanent damage. Delays in diagnosis or misdiagnosis as another condition can lead to irreversible kidney injury. This is why awareness of the disease among healthcare providers is so important, even though aHUS is rare.^[3]

Many patients experience episodes or flares of disease activity that can be triggered by infections, pregnancy, certain medications, or other factors. Even with successful treatment of an initial episode, the risk of recurrence remains throughout a person’s lifetime. The unpredictable nature of these recurrences contributes to emotional stress and uncertainty for patients and their families. However, ongoing treatment with complement inhibitors has been shown to prevent many of these recurrent episodes.^[1]

For those who progress to kidney failure despite treatment, dialysis or kidney transplantation becomes necessary. The recurrence rate of aHUS in transplanted kidneys used to be significant, ranging from about 50 to 90 percent in patients with certain genetic mutations who did not receive preventive treatment. This meant that the disease could destroy a transplanted kidney just as it damaged the original kidneys. However, the use of complement-blocking medications before and after transplantation has dramatically reduced these recurrence rates.^[3]

Long-term complications can affect various organs beyond the kidneys. Some patients develop chronic high blood pressure that requires ongoing medication management. Others may experience neurological effects, cardiovascular problems, or complications affecting the digestive system, liver, or lungs. The extent of multi-organ involvement varies considerably among individuals and influences overall prognosis. Regular monitoring helps detect these complications early when they’re most treatable.^[7]

Quality of life considerations are increasingly recognized as important aspects of prognosis. Even when laboratory values improve with treatment, many adults with aHUS report persistent fatigue that significantly impacts their daily functioning and ability to work. The psychological burden of living with a chronic, potentially life-threatening condition affects both patients and their family members. Fear, guilt, and trauma related to the disease can persist across all phases of illness, highlighting the need for comprehensive care that addresses mental and emotional wellbeing alongside physical health.^[17]

Survival Rate

Historical data from before modern complement-blocking therapies became available showed that atypical hemolytic uremic syndrome had significant mortality rates. Approximately 33 to 40 percent of patients either died or required permanent dialysis after their first clinical presentation, despite receiving supportive care including plasma exchange or infusion. When accounting for subsequent disease relapses over the first year, roughly 65 percent of patients experienced severe outcomes including need for dialysis, permanent kidney damage, or death.^[7]

The introduction of eculizumab and other complement inhibitors has revolutionized survival rates for aHUS patients. Clinical trials of these medications have demonstrated dramatic improvements in outcomes compared to historical controls. Many patients treated with complement inhibitors show rapid improvement in platelet counts, reduction in hemolysis, and recovery of kidney function. The availability of these targeted therapies means that many people diagnosed with aHUS today have a much better chance of survival and preservation of kidney function than patients diagnosed even a decade ago.^[9]

Among children with aHUS, outcomes can vary depending on the age at presentation and underlying genetic cause. Some studies have shown that the typical form of HUS (caused by bacterial toxins) has better outcomes than the atypical form, partly because the atypical form is more likely to cause recurrent episodes and progressive kidney damage. However, with appropriate treatment including complement inhibitors, many children with aHUS can achieve good long-term outcomes. Kidney transplantation is safe and effective for children who progress to end-stage kidney disease, with improved survival of both the patient and the transplanted kidney when complement-blocking medications are used.^[11]

It’s important to understand that survival statistics are based on groups of patients and may not predict what will happen to any individual person. Each patient’s experience with aHUS is unique, influenced by their specific genetic background, overall health, how quickly treatment begins, and many other factors. Some people respond exceptionally well to treatment and maintain good kidney function for many years, while others may have more complicated courses despite receiving appropriate care.^[17]

The rarity of atypical hemolytic uremic syndrome means that survival data comes from relatively small patient populations studied over various time periods. As newer treatments have only become widely available in recent years, long-term survival data with these therapies is still being collected. Ongoing research continues to provide better information about outcomes, helping both patients and doctors understand what to expect and how to optimize care for the best possible results.^[13]

#1 Clinical Trials Search in Europe